Pfizer leaves exec dangling

The New York Times profiles the increasingly isolated world of Peter Rost, the vice president of marketing for Pfizer who has steadfastly advocated allowing reimported drugs from Canada. With no clear responsibilities, no one to report to and no one reporting to him, Rost wonders when Pfizer may get around to firing him. Human resource experts say that Pfizer may just be hoping that Rost quits on his own. Pfizer has been an opponent -- along with much of the rest of the pharmaceutical industry -- of reimporting less expensive drugs from Canada.

- read this article from The New York Times for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.